脊髄性筋萎縮症(SMA)治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0801
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:167
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Spinal Muscular Atrophy (SMA) – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Spinal Muscular Atrophy – Pipeline Review, H1 2020, provides an overview of the Spinal Muscular Atrophy (Central Nervous System) pipeline landscape.

Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important cells are responsible for supplying electrical and chemical messages to muscle cells. Without the proper input from the motor neurons, muscle cells cannot function properly. The muscle cells will, therefore, become much smaller (atrophy) and will produce symptoms of muscle weakness. This can affect walking, crawling, breathing, swallowing, and head and neck control.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Spinal Muscular Atrophy – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Muscular Atrophy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 3, 19 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 7 and 2 molecules, respectively.

Spinal Muscular Atrophy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Muscular Atrophy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Spinal Muscular Atrophy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Spinal Muscular Atrophy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Spinal Muscular Atrophy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Muscular Atrophy (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Spinal Muscular Atrophy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Spinal Muscular Atrophy (SMA) – Overview
Spinal Muscular Atrophy (SMA) – Therapeutics Development
Spinal Muscular Atrophy (SMA) – Therapeutics Assessment
Spinal Muscular Atrophy (SMA) – Companies Involved in Therapeutics Development
Spinal Muscular Atrophy (SMA) – Drug Profiles
Spinal Muscular Atrophy (SMA) – Dormant Projects
Spinal Muscular Atrophy (SMA) – Discontinued Products
Spinal Muscular Atrophy (SMA) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Spinal Muscular Atrophy (SMA), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Allianz Pharmascience Ltd, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Armgo Pharma Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by AveXis Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Biogen Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by BioMarin Pharmaceutical Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Biophytis SA, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Cytokinetics Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Enzerna Biosciences LLC, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Exicure Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Genea Biocells, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by GNT Pharma Co Ltd, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Imago Pharmaceuticals Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Ionis Pharmaceuticals Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Kowa Co Ltd, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Neurodyn Life Sciences Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Neurotune AG, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Novartis AG, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Ractigen Therapeutics Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Reborna Biosciences Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Recursion Pharmaceuticals Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Sarepta Therapeutics Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Scholar Rock Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Shift Pharmaceuticals, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Spotlight Innovation Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Vybion Inc, H1 2020
Spinal Muscular Atrophy (SMA) - Pipeline by Xcelthera INC, H1 2020
Spinal Muscular Atrophy (SMA) - Dormant Projects, H1 2020
Spinal Muscular Atrophy (SMA) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Spinal Muscular Atrophy (SMA) - Discontinued Products, H1 2020

【掲載企業】

Allianz Pharmascience Ltd
Armgo Pharma Inc
AveXis Inc
Biogen Inc
BioMarin Pharmaceutical Inc
Biophytis SA
Cytokinetics Inc
Enzerna Biosciences LLC
Exicure Inc
F. Hoffmann-La Roche Ltd
Genea Biocells
GNT Pharma Co Ltd
Imago Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Kowa Co Ltd
Neurodyn Life Sciences Inc
Neurotune AG
Novartis AG
Ono Pharmaceutical Co Ltd
Ractigen Therapeutics Inc
Reborna Biosciences Inc
Recursion Pharmaceuticals Inc
Sarepta Therapeutics Inc
Scholar Rock Inc
Shift Pharmaceuticals
Spotlight Innovation Inc
Vybion Inc
Xcelthera INC

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[脊髄性筋萎縮症(SMA)治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆